AccutarBio

About AccutarBio

Accutar Biotechnology leverages artificial intelligence (AI) to revolutionize drug discovery, focusing on the physical and chemical nature of biological systems. The company operates in the biotechnology sector, primarily targeting pharmaceutical clients and research institutions. Accutar's business model centers around a hybrid approach that combines computational drug design with wet lab validation, significantly reducing the time and cost associated with traditional drug discovery methods. The company generates revenue through partnerships, licensing agreements, and milestone payments from successful drug development projects. Accutar's recent advancements include FDA clearance for Phase 1 trials of AC0176 for prostate cancer and the dosing of the first patient with AC0682 in a Phase 1 study for ER-positive, HER2-negative breast cancer. The company also boasts a robust drug discovery pipeline and a scientific advisory board featuring award-winning scientists.